» Articles » PMID: 29770618

Peritoneal Cancer Index As a Predictor of Survival in Advanced Stage Serous Epithelial Ovarian Cancer: a Prospective Study

Overview
Journal J Gynecol Oncol
Date 2018 May 18
PMID 29770618
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: A numerical score, the peritoneal cancer index (PCI), was developed to reflect the extent of tumor growth in gastric and colorectal cancers and to tailor treatment. This study aimed to examine the value of the PCI score in advanced epithelial ovarian cancer (EOC) regarding completeness of surgical cytoreduction and survival.

Methods: This was a prospective observational cohort study. Patients with primary serous EOC at International Federation of Gynecology and Obstetrics (FIGO) stages IIIB or higher were included. Patients with FIGO stage IVB as well as those assigned to receive neoadjuvant treatment were excluded from the study. The PCI was obtained and registered intraoperatively.

Results: In the study period we recruited 96 patients with serous EOC stage IIIB-IVA. A PCI score cut-off value of 13 was calculated using a receiver operator characteristic (ROC) curve, above which worse survival is expected (area under the curve [AUC]=0.641; 95% confidence interval [CI]=0.517-0.765; sensitivity and specificity 80.6%, 45.0%, respectively; p=0.050). A multivariate analysis determined that suboptimal surgical cytoreduction was the only independent predictive factor for recurrence (odds ratio [OR]=7.548; 95% CI=1.473-38.675; p=0.015). A multivariate analysis determined that only suboptimal surgical cytoreduction (hazard ratio [HR]=2.33; 95% CI=0.616-8.795; p=0.005), but not PCI score >13 (HR=1.289; 95% CI=0.329-5.046; p=0.716), was an independent predictive factor for death.

Conclusion: We conclude from this study that the PCI score is a reliable tool helping to assess the extent of disease in advanced serous EOC patients and may help predicting complete surgical cytoreduction but cannot qualify as a predictor of survival.

Citing Articles

Surgical and survival outcomes of cytoreductive surgery alone or with perioperative intraperitoneal chemotherapy in high peritoneal cancer index.

Ercan M, Aziret M, Karaman K, Kose O, Oter V, Yirgin H Turk J Surg. 2025; 40(3):219-228.

PMID: 39917404 PMC: 11792903. DOI: 10.47717/turkjsurg.2024.6457.


Textbook outcome in ovarian cancer and its impact on survival: comparative study.

Carbonell-Morote S, Arjona-Sanchez A, Cascales-Campos P, Gonzalez-Gil A, Gomez-Duenas G, Gil-Gomez E World J Surg Oncol. 2025; 23(1):32.

PMID: 39893428 PMC: 11786506. DOI: 10.1186/s12957-025-03686-5.


The Hemodynamic Management and Postoperative Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Prospective Observational Study.

Lal Solanki S, Agarwal V, Ambulkar R, Joshi M, Chawathey S, Rudrappa S Crit Care Res Pract. 2025; 2024:8815211.

PMID: 39760061 PMC: 11698608. DOI: 10.1155/ccrp/8815211.


Δ-Peritoneal Cancer Index (Δ-PCI) to Predict Complete Cytoreduction and Histopathological Response to Neoadjuvant Chemotherapy in Ovarian Cancer.

Spagnol G, Bigardi S, Zorzi M, Morotti M, Carollo M, Bruni G J Clin Med. 2024; 13(22).

PMID: 39598059 PMC: 11595135. DOI: 10.3390/jcm13226915.


Pathological PCI as a prognostic marker of survival after neoadjuvant chemotherapy in patients undergoing interval cytoreduction with or without HIPEC in FIGO stage IIIC high grade serous ovarian cancer.

Sinukumar S, Damodaran D, S D, Piplani S Front Oncol. 2024; 14:1458019.

PMID: 39228986 PMC: 11368729. DOI: 10.3389/fonc.2024.1458019.


References
1.
Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M . Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2013; 21(4):1147-52. DOI: 10.1245/s10434-013-3443-2. View

2.
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe.... Cancer. 2009; 115(6):1234-44. DOI: 10.1002/cncr.24149. View

3.
Bakrin N, Bereder J, Decullier E, Classe J, Msika S, Lorimier G . Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013; 39(12):1435-43. DOI: 10.1016/j.ejso.2013.09.030. View

4.
da Silva R, Sugarbaker P . Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006; 203(6):878-86. DOI: 10.1016/j.jamcollsurg.2006.08.024. View

5.
Goere D, Souadka A, Faron M, Cloutier A, Viana B, Honore C . Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015; 22(9):2958-64. DOI: 10.1245/s10434-015-4387-5. View